EMA gives thumbs up to Olysio

The European Medicines Agency approves Johnson & Johnson's (JNJ) hepatitis C pill Olysio.

The company developed the drug with Sweden's Medivir.

From other sites
Comments (2)
  • MintyFresh32
    , contributor
    Comments (411) | Send Message
    With a company the size of JNJ, each individual announcement like this is unlikely to move the needle. But JNJ is an incredible company, and all of its moves in aggregate make it an excellent core holding for the long term. Join discussion of JNJ as a dividend growth prospect here: http://bit.ly/1givIml.
    21 Mar 2014, 11:28 AM Reply Like
  • earthtodan
    , contributor
    Comments (399) | Send Message
    Thanks for the link, I just joined the forum.
    21 Mar 2014, 04:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs